Compass Therapeutics functions as a clinical-stage biopharmaceutical firm, meaning its long-term investment viability depends entirely on successfully commercializing its drug pipeline. For investors with a high risk tolerance and a multi-year horizon willing to withstand clinical trial uncertainties, it offers targeted sector exposure.